RADNOR, Pa., Jan. 20, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today encouraging in vivo and in vitro data for its novel, defensin-mimetic antimicrobial compounds, which included studies showing efficacy in animal models of oral candidiasis and malaria. The data were presented at the Keystone Symposia on Molecular and Cellular Biology in Santa Fe, New Mexico on January 17 and 18, 2012. The presentations are available on PolyMedix's website at www.Polymedix.com.
